Advertisement

Topics

Latest "Biomarker discovery Driving technologies" News Stories

15:32 EDT 29th April 2017 | BioPortfolio

Here are the most relevant search results for "Biomarker discovery Driving technologies" found in our extensive news archives from over 250 global news sources.

More Information about Biomarker discovery Driving technologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biomarker discovery Driving technologies for you to read. Along with our medical data and news we also list Biomarker discovery Driving technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biomarker discovery Driving technologies Companies for you to search.

Showing "Biomarker discovery Driving technologies" News Articles 1–25 of 18,000+

Extremely Relevant

Biomarker discovery could allow prediction of rheumatoid arthritis outcomes

A biomarker has been found that could make it easier to predict which rheumatoid arthritis patients are at most risk of serious illness. Researchers have discovered that antibodies against the cartilage protein collagen II are associated with better outcomes, and could be helpful in determining the best treatment to use for individual people. Healthcare professionals […] The post Biomarker d...


Relevant

Stemina Biomarker Discovery, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350

SummaryMarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.MarketLines' Stemina Biomarker Discovery, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, det...

Agilent Technologies, Transcriptic collaborate to automate discovery biology

Agilent Technologies and Transcriptic have agreed to partner their technologies to provide a solution for convenient, broad scale synthetic and discovery biology research. Agilent continues its strong program of fostering innovation using the Agilent portfolio by collaborating with rising companies such as Transcriptic to develop novel synthetic biology solutions. Transcriptic’s automated discov...


Bristol-Myers Squibb and Nordic Bioscience Collaborate for Fibrosis Biomarker Technology

NEW YORK & HERLEV, Denmark–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over ...

Carmentix and the University of Melbourne announce “Preterm Birth Biomarker Discovery” initiative

This collaborative clinical study aims to validate novel biomarkers discovered by Carmentix. The post Carmentix and the University of Melbourne announce “Preterm Birth Biomarker Discovery” initiative appeared first on PharmaAsia.

Bristol-Myers Squibb, Nordic Bioscience collaborate on fibrosis biomarker technology

Bristol-Myers Squibb and Nordic Bioscience, a Danish company specializing in biomarker technologies, announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over 25 years’ experience in biomarker development and clinical trials with extensive ...

Agilent Technologies and Transcriptic Collaborate to Automate Discovery Biology

Agilent Technologies Inc. and Transcriptic Inc. have agreed to partner their technologies to provide a solution for convenient, broad scale synthetic and discovery biology research. Agilent continues its strong program of fostering innovation using the Agilent portfolio by collaborating with rising ...

Global Cancer Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 2022 Prices from USD $3900

The global cancer biomarkers market is anticipated to reach around $17 billion by 2022, with an estimated CAGR of 12.6% from 2016 to 2022. The market growth is driven by factors such as increasing prevalence of cancer, various technological developments in omics technologies; increased demand for personalized medicines especially in cancer therapies, rising number of clinical trials in developed a...

Global Cancer Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 2022 Prices from USD $5900

The global cancer biomarkers market is anticipated to reach around $17 billion by 2022, with an estimated CAGR of 12.6% from 2016 to 2022. The market growth is driven by factors such as increasing prevalence of cancer, various technological developments in omics technologies; increased demand for personalized medicines especially in cancer therapies, rising number of clinical trials in developed a...

Lantern Pharma, Intuition Systems partner in biomarker discovery

Lantern Pharma has reached an agreement to collaborate with India-based AI and data analytics company, Intuition Systems. Lantern Pharma is a privately held, global biotech company pioneering the field of precision oncology. Lantern’s proprietary approach to drug development is driven by advanced genomics and machine learning-based artificial intelligence (AI), which when combined, are advancing...

Bridging the translational innovation gap through good biomarker practice

Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way to developing and sharing best practices for biomarker validation.

Evotec, Merck sign deals to partner on target discovery technologies

Evotec and Merck have signed agreements to collaborate on target discovery technologies.

ReproCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery / Alliance provides wider access to oncology biospecimens to accelerate discovery and translational studies

BELTSVILLE, MD and PHILADELPHIA, PA -- (Marketwired) -- 04/13/17 -- ReproCELL and Fox Chase Cancer Center today announced a strategic alliance aimed at accelerating oncology discovery and translat...

AsiaPacific Next Generation Sequencing NGS market by Product software and services by Technology whole targeted resequencing, genome sequencing, de novo sequencing, exome sequencing, RNASeq, ChIPSeq and MethylSeqby application diagnostics, drug discove

The AsiaPacific NGS market which was worth $ 567.7 million in 2016 is poised to reach$1,636.7 million by 2021 at a CAGR of 23.59%. Asia presents significant opportunities for theinvestors/venture capitalists as the developed markets are saturated. The presence of noteworthydevelopments by China and Japan for integration of new technologies and the development ofhealthcare is majorly driving the As...

New biomarker is higher in suicide attempters and associated with stress response

Researchers at Lund and Malmö universities in Sweden have measured a biomarker in cell-free blood plasma which can be linked to an overactive stress system in suicidal individuals. This biomarker can hopefully be used in future psychiatric studies.

Agilent, Transcriptic Partner on Biologic Discovery Solutions

Will combine technologies to provide a solution for convenient, synthetic and discovery biology research

BRIEF-Evotec, Merck to collaborate on target discovery technologies

* Evotec and Merck enter into agreements to collaborate on target discovery technologies Source text for Eikon: Further company coverage:

Evotec, Merck to collaborate on target discovery technologies

Evotec has announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck’s portfolio of genome editing technologies with Evotec’s versatile screening platforms and disease expertise. Evotec will leverage Merck’s comprehensive collection of genetic reagents such as viral CRISPR and shRNA libraries to enable new target ...

Latest advances in artificial intelligence for drug discovery to be presented at the NVIDIA GTC

(InSilico Medicine, Inc.) Insilico Medicine, Inc, is a big data analytics company specializing in applying the latest advances in deep learning to drug discovery, biomarker development and aging research. In the NVIDIA Graphics Technology Conference (GTC), the scientists from Insilico Medicine will present its latest progress on the applications of Generative Adversarial Networks to Drug Discovery...

Japan Safety Biomarker Workshop

(The Critical Path Institute (C-Path)) The Japan Safety Biomarker Workshop, held February 20-21 at the RIKEN Institute, in Yokohama, Japan, assembles leading scientists and researchers from industry and academia, and government regulatory authorities. Attendees will gain perspective on biomarker development and biomarker application in preclinical and clinical research. Topics include an overview ...

Global Central Nervous System CNS Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 2022 Prices from USD $3900

A biomarker is biological feature that can be used to measure the presence or progress of disease or the effects of treatment. For example, prostate specific antigen PSA is a biomarker for cancer of prostate. Biomarkers enable the researchers to quickly see large number of biological analytics. In the present scenario, the research and development in CNS market has paced up due to support from gov...

Global Central Nervous System CNS Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 2022 Prices from USD $5900

A biomarker is biological feature that can be used to measure the presence or progress of disease or the effects of treatment. For example, prostate specific antigen PSA is a biomarker for cancer of prostate. Biomarkers enable the researchers to quickly see large number of biological analytics. In the present scenario, the research and development in CNS market has paced up due to support from gov...

Cancer Genetics Is Selected By eFFECTOR To Provide Biomarker Discovery And Development Services For Novel Oncology Drugs

  Life Sciences Jobs   ...

FNIH releases final biomarker framework

The Foundation for the National Institutes of Health (FNIH) released its framework outlining basic evidence required for biomarker qualification. The framework is designed to provide predictable and specific regulatory criteria, and was produced through collaboration among FNIH, FDA, NIH, the

Insilico Medicine to present research findings in AI for drug discovery at BioDataWorld West Congress

Insilico Medicine, a Baltimore-based Big Data analytics company applying deep learning techniques to drug discovery, biomarker development and human longevity research will present and chair a panel at the BioDataWorld West, San Francisco, April 26-27.


Quick Search
Advertisement
 

News Quicklinks